Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Young R Lee, Coovi Houngue & Ronald G Hall. (2015) Treatment of community-acquired pneumonia. Expert Review of Anti-infective Therapy 13:9, pages 1109-1121.
Read now
Read now
Brian Wispelwey & Katherine R Schafer. (2010) Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert Review of Anti-infective Therapy 8:11, pages 1259-1271.
Read now
Read now
Olaf Burkhardt & Tobias Welte. (2009) 10 years’ experience with the pneumococcal quinolone moxifloxacin. Expert Review of Anti-infective Therapy 7:6, pages 645-668.
Read now
Read now
Georg Cachovan, Ibrahim Nergiz, Uwe Thuss, Hans-Martin Siefert, Ingo Sobottka, Okhan Oral, Ursula Platzer & Özen Dogan-Onur. (2009) Penetration of moxifloxacin into rat mandibular bone and soft tissue. Acta Odontologica Scandinavica 67:3, pages 182-186.
Read now
Read now
Hartmut M Lode & Malina Schmidt-Ioanas. (2008) Moxifloxacin: update and perspectives after 8 years of usage. Expert Review of Respiratory Medicine 2:4, pages 443-453.
Read now
Read now
Gopal Krishna, Mark H. Gotfried, Kenneth Rolston & Zaiqi Wang. (2007) Penetration of garenoxacin into lung tissues and bone in subjects undergoing lung biopsy or resection. Current Medical Research and Opinion 23:8, pages 1841-1847.
Read now
Read now
Anna M Ferrara. (2007) A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP). Clinical Interventions in Aging 2:2, pages 179-187.
Read now
Read now
Johannes Beckmann, Frieder Kees, Jens Schaumburger, Thomas Kalteis, Norbert Lehn, Joachim Grifka & Klaus Lerch. (2007) Tissue concentrations of vancomycin and Moxifloxacin in periprosthetic infection in rats. Acta Orthopaedica 78:6, pages 766-773.
Read now
Read now
F.M.E. Wagenlehner, J.C. Lunz, F. Kees, W. Wieland & K.G. Naber. (2006) Serum and Prostatic Tissue Concentrations of Moxifloxacin in Patients Undergoing Transurethral Resection of the Prostate. Journal of Chemotherapy 18:5, pages 485-489.
Read now
Read now
Articles from other publishers (22)
Fabio Borgonovo, Massimiliano Quici, Antonio Gidaro, Davide Giustivi, Dario Cattaneo, Cristina Gervasoni, Maria Calloni, Elena Martini, Leyla La Cava, Spinello Antinori, Chiara Cogliati, Andrea Gori & Antonella Foschi. (2023) Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review. Antibiotics 12:8, pages 1338.
Crossref
Crossref
Lloyd Tanner, Gabriel T. Mashabela, Charles C. Omollo, Timothy J. de Wet, Christopher J. Parkinson, Digby F. Warner, Richard K. Haynes & Lubbe Wiesner. (2021) Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy. Microbiology Spectrum 9:2.
Crossref
Crossref
Donald J. AbrahamCourtney C. Aldrich, Robert S. Wallis, Rory P. Remmel, Pooja Hegde & Christina L. Stallings. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
110
.
Irene Karampela & Maria Dalamaga. (2020) Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?. Archives of Medical Research 51:7, pages 741-742.
Crossref
Crossref
Basanth Babu Eedara, Ian G. Tucker, Zoran D. Zujovic, Thomas Rades, Jason R. Price & Shyamal C. Das. (2019) Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. European Journal of Pharmaceutical Sciences 136, pages 104961.
Crossref
Crossref
Elias Polykandriotis, Raymund E. Horch, Matthias Jost, Andreas Arkudas, Frieder Kees & Marweh Schmitz. (2019) Can systemically administered antibiotics be detected in wound tissues and surfaces under negative pressure wound therapy?. International Wound Journal 16:2, pages 503-510.
Crossref
Crossref
Maria Sionidou, Katerina Manika, Georgia Pitsiou, Paschalina Kontou, Kalliopi Chatzika, Paul Zarogoulidis & Ioannis Kioumis. (2019) Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy 63:3.
Crossref
Crossref
M Tobias Heinrichs, Sergo Vashakidze, Ketino Nikolaishvili, Irina Sabulua, Nestani Tukvadze, Nino Bablishvili, Shota Gogishvili, Brent P Little, Adam Bernheim, Jeannette Guarner, Charles A Peloquin, Henry M Blumberg, Hartmut Derendorf & Russell R Kempker. (2018) Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. Journal of Antimicrobial Chemotherapy 73:2, pages 477-483.
Crossref
Crossref
Tobias Welte. (2015) Managing CAP patients at risk of clinical failure. Respiratory Medicine 109:2, pages 157-169.
Crossref
Crossref
Hartmut M. Lode. (2014) Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes. International Journal of Antimicrobial Agents 43:6, pages 497-507.
Crossref
Crossref
Elisa Chilet-RosellMa Teresa Ruiz-CanteroMa Angeles Pardo. (2014) Gender Analysis of Moxifloxacin Clinical Trials. Journal of Women's Health 23:1, pages 77-104.
Crossref
Crossref
M. G. Kees, S. Weber, F. Kees & T. Horbach. (2011) Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. Journal of Antimicrobial Chemotherapy 66:10, pages 2330-2335.
Crossref
Crossref
Koichiro Yoshida, Yoshihito Niki, Niro Okimoto, Michihiro Kishimoto, Hiroshi Fukano, Hiroki Hara, Toshiharu Matsushima, Hirohide Yoneyama, Osamu Moriya, Masayoshi Kawanishi & Makoto Kimura. (2011) Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. Journal of Infection and Chemotherapy 17:5, pages 678-685.
Crossref
Crossref
Donald J. AbrahamCourtney C. Aldrich, Helena I. Boshoff & Rory P. Remmel. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
711
810
.
Donald J. AbrahamVergnaud Jean‐Maurice & Rosca Iosif‐Daniel. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
753
866
.
T. Bschleipfer, F.M.E. Wagenlehner & W. Weidner. (2007) Beeinflussbarkeit histopathologischer Entzündungsgrade bei asymptomatischer Prostatitis (NIH IV) durch Moxifloxacin. Der Urologe 46:9, pages 1027-1030.
Crossref
Crossref
E. Denes. (2006) Quel antibiotique pour une pneumonie aiguë communautaire de l'adulte ?. Médecine et Maladies Infectieuses 36:11-12, pages 718-733.
Crossref
Crossref
B. Fantin. (2006) 05 – Diffusion sérique et respiratoire des antibiotiques. Analyse critique des paramètres prédictifs d'efficacité clinique. Médecine et Maladies Infectieuses 36:11-12, pages 599-613.
Crossref
Crossref
L. Malincarne, M. Ghebregzabher, M. V. Moretti, A. M. Egidi, B. Canovari, G. Tavolieri, D. Francisci, G. Cerulli & F. Baldelli. (2006) Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. Journal of Antimicrobial Chemotherapy 57:5, pages 950-954.
Crossref
Crossref
Silvano Esposito, Silvana Noviello, Gioacchino D'Errico, Gaetano Motta, Desiderio Passali, Claudia Aimoni, Stefano Pilucchi, Stefania Fallani, Maria Iris Cassetta, Teresita Mazzei & Andrea Novelli. (2006) Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. Journal of Antimicrobial Chemotherapy 57:4, pages 789-792.
Crossref
Crossref
Vincent T Andriole, Daniel C Haverstock & Shurjeel H Choudhri. (2005) Retrospective Analysis of the Safety Profile of Oral Moxifloxacin in Elderly Patients Enrolled in Clinical Trials. Drug Safety 28:5, pages 443-452.
Crossref
Crossref
Gillian M Keating & Lesley J Scott. (2004) Moxifloxacin. Drugs 64:20, pages 2347-2377.
Crossref
Crossref